Review Article
Identifying and Overcoming Perceived Barriers of Providers towards HPV Vaccination: A Literature Review
| Vaccine | Indications | HPV types | Contraindication | Efficacy |
| Cervarix/2vHPV (Merck) | Cervical precancer and cancer | 16 and 18 | Latex hypersensitivity | 92.9% |
| Gardasil/4vHPV (GlaxoSmithKline) | Cervical cancers Cervical, vaginal, vulvar, and anal cancers and genital warts | 6, 11, 16, 18 | Yeast hypersensitivity | 98–100% |
| Gardasil 9/9vHPV (Merck) | Cervical, vaginal, vulvar, and anal cancers and genital warts | 6, 11, 16, 18 31, 33, 45, 52, 58 | | 96.3–96.7% |
|
|